Peng Mei News (www.thepaper.cn) reporter learned from BeiGene that on June 12, Zebutinib’s pricing information in China was officially linked to The price of 68 capsules per box and 11300 yuan is listed in the country, and the monthly treatment fee is 22600 yuan.
According to the State Food and Drug Administration, Zebutinib is a selective inhibitor of Bruton’s tyrosine kinase (BTK), and Zebutinib capsules are our country Innovative medicine developed independently and with independent intellectual property rights. The listing of this product will provide more medication options for patients with adult mantle cell lymphoma and adult chronic lymphocytic leukemia/small lymphocytic lymphoma.
On June 3, Zebutinib, a subsidiary of BeiGene, was approved in China for adult mantle cell lymphoma (MCL) who had received at least one treatment in the past ) Patients and adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients who have received at least one treatment in the past.
According to the instructions of Zebutinib in China, the recommended dosage for MCL and CLL/SLL patients is two 80mg capsules each time, orally, daily twice.
According to the introduction of Beiji Shenzhou, the current packaging specification of Zebutinib is 64 80mg capsules per box, each box is roughly equivalent to half a month of treatment, out Due to human considerations, an additional 4 capsules are added per box.
Zebutinib is the first domestic BTK inhibitor to be marketed in China. Prior to this, Ibinib, which is also a BTK inhibitor, has been listed in China in 2017 .
It is understood that the price of Ibutinib at the time when it was approved was 48,600 yuan per month. After the national medical insurance negotiations reduced the price in 2018, for chronic lymphocytic leukemia (CLL ) For patients, the monthly drug price is 17010 yuan before reimbursement. For patients with mantle cell lymphoma (MCL), due to different drug usage, the monthly drug price is about 22680 yuan before reimbursement.
BeiGene said that the initial pricing of Zebutinib is close to the price of Ibutinib after medical insurance negotiations. For MCL patients, Zebutinib’s The monthly treatment fee is even lower than the monthly price of 22,680 yuan after the negotiated price reduction of the Ibutinib medical insurance.
Beiji also said that it is actively exploring a variety of innovative payment methods, hoping to further help patients to improve the benefits of treatment. At the same time, Beiji Shenzhou looks forward to close communication with the medical insurance department to achieve Zebutinib is included in the medical insurance catalog to help patients further reduce the burden of medication.